Series Unknown Funded Biotechnology Startups
The 50 most recent Series Unknown rounds in biotechnology run from August 6 to August 27, 2025, and span a wide range of deal sizes — from $250,000 (Polari…
The 50 most recent Series Unknown rounds in biotechnology run from August 6 to August 27, 2025, and span a wide range of deal sizes — from $250,000 (Polaris Genomics, Gaithersburg) to $1.5 billion (ALT5 Sigma Corp, Minneapolis). Five rounds exceeded $100 million: ALT5 Sigma Corp, ADMA Biologics ($300 million, Ramsey, New Jersey), BBOT ($261 million, Palo Alto), Heron Therapeutics ($145 million, Redwood City), and Compass Therapeutics ($120 million, Boston). Seven companies did not disclose amounts, including Arvinas (New Haven), Superluminal Medicines (Boston), and Phytolon (Israel).
California accounts for the largest cluster of companies, with activity across San Diego, Carlsbad, Emeryville, Redwood City, and Palo Alto — roughly 14 of the 50 rounds shown. Massachusetts is the second-most-represented state, anchored by Cambridge and Boston. Eleven of the 50 rounds are headquartered outside the United States, spanning Israel (four companies), Canada, the United Kingdom, France, Sweden, and Australia.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these 50 biotechnology companies?
The five largest are ALT5 Sigma Corp ($1.5 billion, Minneapolis, August 11), ADMA Biologics ($300 million, Ramsey, New Jersey, August 6), BBOT ($261 million, Palo Alto, August 11), Heron Therapeutics ($145 million, Redwood City, August 8), and Compass Therapeutics ($120 million, Boston, August 12).
How many of these rounds did not disclose a dollar amount?
Seven of the 50 rounds are listed as undisclosed: Arvinas (New Haven, Connecticut), Inso Biosciences (Ithaca, New York), Superluminal Medicines (Boston), Phytolon (Israel), Panthera Biopartners (Preston, UK), Geltor (Emeryville, California), and Processa Pharmaceuticals (Hanover, Maryland).
Which cities and states appear most frequently in this dataset?
California is the dominant state, with companies in San Diego (Debut, aTyr Pharma, Belite Bio), Carlsbad (Lineage Cell Therapeutics, Capienda Biotech), Emeryville (Bolt, Geltor), and Palo Alto (BBOT), among others. Massachusetts is second, with Cambridge hosting Immuneering and X4 Pharmaceuticals and Boston hosting Compass Therapeutics and Superluminal Medicines — all within the same three-week window.
How do disclosed deal sizes distribute across this set?
Of 43 rounds with disclosed amounts, eight exceed $50 million — led by ALT5 Sigma Corp ($1.5 billion), ADMA Biologics ($300 million), and BBOT ($261 million). The remaining 35 disclosed rounds fall at or below $50 million, with several under $1 million: Polaris Genomics at $250,000, Capienda Biotech at $330,000, and Minovia at $350,000.
Which non-U.S. countries are represented in this biotechnology funding data?
Israel leads with four companies — Minovia (Tirat Carmel), Neurolief (Netanya), NurExone Biologic (Haifa), and Phytolon — followed by Canada with Cannara Biotech (Montreal) and Devonian Health Group (Pointe-Claire), and the United Kingdom with Neurovalens (Belfast) and Panthera Biopartners (Preston). France (Osivax, Lyon), Sweden (Anocca, Södertälje), and Australia (Propanc, Melbourne) each contribute one company.
Which dates saw the most biotechnology funding activity in this period?
August 7 and August 19 were each the busiest single days, with six companies raising on each date. August 7 included aTyr Pharma, BioVie, Geltor, Devonian Health Group, Longeviti, and Processa Pharmaceuticals. August 19 brought Continuity Biosciences, Encision, iBio, Neurovalens, OSPRI, and Trethera.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.